Contemporary application of artificial intelligence in prostate cancer: an i-TRUE study. (January 2021)

• Record Type: Journal Article
• Authors: Hameed, B. M. Zeeshan; Shah, Milap; Naik, Nithesh; Ibrahim, Sufyan; Somani, Bhaskar; Rice, Patrick; Soomro, Naeem; Rai, Bhavan Prasad
• Is Part Of: Therapeutic advances in urology. Volume 13(2021)
• Publication Date: 2021-01
• Subjects: artificial intelligence -- deep learning -- prostate cancer -- prostate specific antigen -- machine learning -- uro-oncology; Urology -- Periodicals; Urologic Diseases -- therapy -- Periodicals; Genital Diseases, Male -- therapy -- Periodicals; Urologie -- Périodiques; 616.6005
• DOI: 10.1177/1756287220986640
• Languages: English
• ISSNs: 1756-2872

Abstract

Artificial intelligence (AI) involves technology that is able to emulate tasks previously carried out by humans. The growing incidence, novel diagnostic strategies and newer available therapeutic options have had resource and economic impacts on the healthcare organizations providing prostate cancer care. AI has the potential to be an adjunct to and, in certain cases, a replacement for human input in prostate cancer care delivery. Automation can also address issues such as inter- and intra-observer variability and has the ability to deliver analysis of large volume datasets quickly and accurately. The continuous training and testing of AI algorithms will facilitate development of futuristic AI models that will have integral roles to play in diagnostics, enhanced training and surgical outcomes and developments of prostate cancer predictive tools. These AI related innovations will enable clinicians to provide individualized care. Despite its potential benefits, it is vital that governance with AI related care is maintained and responsible adoption is achieved.